Kraków, Poland, September 26, 2011 / B3C newswire / - Selvita S.A., Poland based integrated drug discovery services provider, announced today signature of an agreement with Evestra GmbH (Germany), a subsidiary of Evestra Inc (USA), for the delivery of a series of drug metabolism, pharmacokinetic (DMPK) and physicochemical studies.
The contracted project involves a set up and implementation of drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability, as well as oral bioavailability and pharmacokinetics assays, both in vitro and in vivo, accompanied by gentotoxicity testing.
“We are keen to take advantage of Selvita’s know-how to support the process of further development of our project. We’re reassured of the competences that Selvita’s team has and high quality of service they deliver. We truly hope this cooperation will provide a value added for Evestra.” – said Klaus Nickisch, Executive Vice President, Chief Scientific Officer, Evestra Inc.
“We are very glad that we can conduct this project for Evestra. Evestra’s choice to entrust Selvita with their project is not only a nobilitation for us, but also gives our research team a chance to show their potential and capabilities to run complex projects in yet another field of preclinical research” – said Dr Milosz Gruca, Selvita’s Head of Biology Department.
About Evestra, Inc.
Evestra, Inc. is an emerging biopharmaceutical research and development company with a focus on female healthcare product development. Evestra's mission is to improve the health and wellness of women around the world through innovative technologies and commercially viable products focused primarily on gynecological disorders, breast cancer and fertility control. Evestra's facilities are located on the Tx Biomed campus, where drug substance can be manufactured under GMP regulationns. Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical needs areas of women's health such as endometriosis and hormonal-dependent breast cancer. The company is also pursuing new compounds for HRT and has established a strong intellectual property position.
About Selvita Group
Selvita Group is an independent integrated drug discovery provider. Selvita offers its clients services ranging from computational chemistry, through chemical development to preclinical in vitro research, done in-house. Company’s mission is to serve its clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating the introduction of new drugs to the market. Since 2010, Selvita is the owner of BioCentrum, which provides in vitro preclinical ADMET services, analytical services and biochemistry services with special focus on protein engineering and antibody development. Selvita' Group laboratories are certified with the Good Laboratory Practice (GLP) certificate, as well as have the accreditation of Polish General Pharmaceutical Inspectorate.
Media contact
Natalia Pawela
This email address is being protected from spambots. You need JavaScript enabled to view it.
+48 12 297 47 31